Antonio Gnoni

Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study

Palma Fedele, Alessandro Rizzo, Matteo Landriscina, Luigia Stefania Stucci et autres

it (code pays fourni par la source)

Early First-Line Therapeutic Attrition After Metastatic Recurrence in Triple-Negative Breast Cancer Following Neoadjuvant Chemo-Immunotherapy: A Multicenter Real-World Study

Palma Fedele, Alessandro Rizzo, Matteo Landriscina, Stefania Luigia Stucci et autres

it, br (code pays fourni par la source)

BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis

Palma Fedele, Alessandro Rizzo, Matteo Landriscina, Luigia Stefania Stucci et autres

Background: Pembrolizumab has reshaped the neoadjuvant treatment landscape for triple-negative breast cancer (TNBC). However, the influence of BRCA1/2 mutational status on the efficacy of chemo-immunotherapy remains unclear, particularly in real-world settings. Since BRCA-mutated tumors exhibit homologous recombination deficiency (HRD) and high genomic …

it (code pays fourni par la source)

BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis

Palma Fedele, Alessandro Rizzo, Matteo Landriscina, Luigia Stefania Stucci et autres

Introduction: Pembrolizumab has reshaped the neoadjuvant treatment landscape for triple-negative breast cancer (TNBC). However, the influence of BRCA1/2 mutational status on the efficacy of chemo-immunotherapy remains unclear, particularly in real-world settings. Since BRCA-mutated tumors exhibit homologous recombination deficiency (HRD) and high genomic …

it (code pays fourni par la source)

Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis

Palma Fedele, Luigia Stefania Stucci, Matteo Landriscina, Maria Grazia Morritti et autres

Background: Pembrolizumab combined with neoadjuvant chemotherapy significantly improves pCR in early TNBC, but the effect of treatment intensity and baseline clinical factors has been insufficiently explored in real-world settings. Methods: We retrospectively included 169 consecutive patients with stage II–III TNBC treated across …

it (code pays fourni par la source)

CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study

Palma Fedele, Matteo Landriscina, Lucia Moraca, Antonio Cusmai et autres

Background: Older adults aged ≥80 with HR+/HER2− metastatic breast cancer (MBC) are often underrepresented in clinical trials, leaving clinicians with limited data to guide treatment decisions. Given the increasing prevalence of this age group, real-world evidence is crucial to inform therapeutic strategies. …

it (code pays fourni par la source)

Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study

Palma Fedele, Matteo Landriscina, Lucia Moraca, Antonio Cusmai et autres

BACKGROUND: Metastatic HR+/HER2- breast cancer is commonly treated with CDK4/6 inhibitors in combination with endocrine therapy. However, the efficacy and safety of this approach in elderly patients (≥70 years) remain unclear, particularly in the context of real-world clinical practice. This study aims …

it (code pays fourni par la source)

List of contributors

Rocı́o Abia, H. Abouloifa, Adriana Morales-Martínez, Diwakar Aggarwal et autres

es, Maroc, mx, in, gr, jo, ro, Égypte, us, Tunisie (code pays fourni par la source)

Immune system and bone microenvironment: rationale for targeted cancer therapies

Antonio Gnoni, Oronzo Brunetti, Calabrese Angela, Roberto Calbi et autres

// Gnoni Antonio 1 , Brunetti Oronzo 2 , Longo Vito 3 , Calabrese Angela 4 , Argentiero Antonel-la 2 , Calbi Roberto 5 , Solimando Antonio Giovanni 6 and Licchetta Antonella 1 1 Medical Oncology Unit, “S. Cuore di Gesù” Hospital, …

it (code pays fourni par la source)

Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies

Antonio Gnoni, Antonella Licchetta, Riccardo Memeo, Antonella Argentiero et autres

The few therapeutic strategies for advance hepatocellular carcinoma (HCC) on poor knowledge of its biology. For several years, sorafenib, a tyrosine kinase inhibitors (TKI) inhibitor, has been the approved treatment option, to date, for advanced HCC patients. Its activity is the inhibition …

it (code pays fourni par la source)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Vito Longo et autres

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib …

it (code pays fourni par la source)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Vito Longo, Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta et autres

Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70-80% of patients are diagnosed at an advanced stage with a dismal prognosis. Sorafenib had been the standardcare for almost a …

it (code pays fourni par la source)